NVS - Novartis AG
Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug Entresto. CEO Vas Narasimhan discussed the company's strategic focus on navigating significant patent expiries in the first half of the year, followed by a growth phase in the second half fueled by investments in the pipeline and new product launches.
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stock futures are rising after three straight days of declines for major indexes; chip stocks are leading the rebound as volatility in the AI trade persists; several big-name companies reported earnings this morning ahead of Big Tech results tomorrow; Nebius shares are surging on news Nvidia as increased its stake in the Dutch AI infrastructure company; and SpaceX shares are rising after closing lower for the seventh consecutive sessions. Here's what you need to know today.
Novartis AG (NYSE:NVS) reported better-than-expected second-quarter earnings on Tuesday as strong demand for its priority medicines offset the impact of generic competition, while the Swiss drugmaker reaffirmed its full-year 2026 guidance.
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected for the company in the second half of the year.
Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-expected costs helped the Swiss drugmaker offset a sharp decline in sales of its top-selling heart failure drug Entresto.
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
Novartis' second-quarter core operating profit beat market expectations on Tuesday, helped by strong sales of cancer and multiple sclerosis drugs.
Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto. We are encouraged by the early trajectory of our recent launches, Rhapsido in CSU and Itvisma. We also made meaningful pipeline progress, highlighted by updated Kisqali overall survival data in early breast cancer and the FDA accelerated approval submission for del-zota in DMD. We are on track for multiple important readouts ahead in the second half, and remain on track to deliver our full-year guidance and mid-term outlook.
While the first quarter showed weaker revenue and earnings, management had already warned that 2026 would begin with significant pressure from generic competition. The key question for traders and investors is whether Novartis' newer medicines are growing quickly enough to offset those losses.
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Dimensional Fund Advisors LP reduced its stake in shares of Novartis AG (NYSE: NVS) by 4.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,110,116 shares of the company's stock after selling 414,278 shares during the period. Dimensional Fund
Boston Common Asset Management LLC lessened its position in shares of Novartis AG (NYSE: NVS) by 4.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,116 shares of the company's stock after selling 5,150 shares during the quarter. Novartis comprises
Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation.
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.